Lecture 2 Flashcards

* main stages of drug discovery and development * Overview of major body systems affected

1
Q

Rationale Drug Design

A

Validated biological Targetversus Drug(that optimally interacts with the target) Triggering of desired biological action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Receptor-based drug design

A

3D structure analysis of biological target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pharmacophore-based drug design

A

Structures of known active small molecules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Main stages of drug discovery and development.

A

Drug Discovery, Preclinical Development Phase, Clinical Development Phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Drug Discovery

A

Identification of candidate molecules on their pharmacological, biochemical and physicochemical properties.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Preclinical development

A

Non-human studies to determine basic pharmacokinetics, potential toxic side effects and formulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinical Development

A

Determination of efficacy, side effects and optimum dosage in volunteers and patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe (i) of Drug Development

A

(a). Chemical or biochemical synthesis of novel compound.
(b). Isolation of active ingredient from natural source
(c). Production and isolation of Biologicals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

(ii) of Drug Development

A

Pre-clinical testing 1: effects of drug on cellular function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

(iii) Drug Development

A

Pre-clinical testing 2: Mechanism of drug action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

(iv) of Drug Development

A

Pre-clinical testing 3: Toxicity testing (in vivo & in vitro & ex vivo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

(v) of Drug Development

A

Phase 0 - human micro dosing. Pharmacokinetic profile of extremely low, non-pharmacological drug doses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

(vi) Drug Development

A

(vi) Phase 1 - clinical trial : on healthy subjects
Effects on body functions; drug safety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

(vii) Drug Development

A

(vii) Phase 2 - clinical trial: on selected patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

(viii) Drug Development

A

(viii) Phase 3 - clinical trial: on large groups of patients
- Comparision to other therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

(ix) Drug Development

A

Approval: Licensing by National Regulatory Agency

17
Q

Drug Development (x)

A

Phase 4-clinical trial: Long-term benefit-risk evaluation Determination of THERAPEUTIC VALUE of novel drug or delivery system

Post-marketing of novel substance (post-licensing studies) - pharmacovigilance

18
Q

What is target selection and what is of based on?

A
  • Target selction: usually a defined protein species
  • Often based on biomedical knowledge on, disease mechanisms, biochemical pathways and cellular signaling.
19
Q

Drug Discovery - identification of lead compound

A
  • Large compound libraries
  • High-throughput HTP screening of 1000s of compounds
  • Determination of half-maximal effective concentration Ec50 of novel compound after a specified exposure time.
20
Q

What animals are used in the detmination of median effective dose ED50?

A

Mice, rats, rabbits

21
Q

Assement of toxicity

A
  • single dose of increasing strength (2 species, both sexes, different ages)
  • different routes of administration (1-7 days)
  • Determination of median lethal dose LD50
22
Q

Assessement of subacute toxicity

only done once lethal dose has been determined.

A
  • several routes of administration (2-12 weeks0
  • several species; several dosages.
23
Q

Assessment of chronic toxicity

A
  • chronic 3-12 months testing in several species
  • evaluation of potential carcinogenic effects
  • special teratogenic tests on pregnant rats
24
Q

Health interventions that require differing degrees of testing are?

A
  • Pharmaceutical agents
  • Novel drug derivatives
  • New drug combinations
  • Diagnostics
  • Medical devices
  • Therapy protocols
25
Q

How are preclinical and clinical trials organised?

A
  • organised in a sequential series of scientific and medical examinations to determine essential data sets on the safety and the efficacy of novel health interventions
26
Q

Initial requirement prior to start of extensive clinical trials

A

-Provision of satisfactory information on the quality of nonclinical safety to National Health Authority
-Ethical approval by an independent National Ethics Committee

27
Q

Authorisation to conduct a clincal trial

A
  • Pharmaceutical company
  • Commissioned to medical institution
  • Commissioned to academic institution
  • Specialist clinical research company
28
Q

To ensure compliance with Irish/European regulation

A
  • Regular audits of clinical trials by the IMB.
  • In Europe, all clinical trial have to be carried out in accordance with the Good Clinical Practice (GCP) regulations of EU Directive 2001/20, article 1, clause 2:
29
Q

Analogue drugs

A

Imitation of chemical structure due to slight, but biochemically irrelevant, modifications of established drug molecule

30
Q

New Drug Combinations

A

Essential active substance plus low-dose indifferent second substance